Welcome to MutualFunds.com. Please help us personalize your experience.
Your personalized experience is almost ready.
Thank you!
Check your email and confirm your subscription to complete your personalized experience.
Thank you for your submission, we hope you enjoy your experience
Find the latest content and information here about the 2019 Charles Schwab Impact Conference.
18 Most Popular Mutual Fund Categories
View All Categories
15 Most Popular Fund Company Quick Screens
View All Fund Company Quick Screens
Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.
Content focused on helping financial advisors build successful client relationships and grow their business.
Content geared towards helping financial advisors build better client portfolios.
Get insights on the industry trends and investment news from leading fund managers and experts.
The fund seeks investments whose prices will increase over time. It normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the healthcare sector. The fund is non-diversified.
Sign up for Advisor Access to receive email updates about PHSZX competitors, news, CE accredited webcasts and more.
| Period | PHSZX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 2.6% | 0.0% | 6.1% | 26.36% |
| 1 Yr | 18.6% | 2.6% | 41.8% | 42.02% |
| 3 Yr | 14.6%* | -9.3% | 27.6% | 21.10% |
| 5 Yr | 6.3%* | -9.8% | 14.7% | 29.25% |
| 10 Yr | 17.1%* | -0.8% | 18.8% | 3.30% |
* Annualized
| Period | PHSZX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2019 | 15.2% | 5.7% | 55.4% | 73.95% |
| 2018 | -13.5% | -25.3% | 21.5% | 81.98% |
| 2017 | 25.8% | -10.8% | 43.9% | 14.68% |
| 2016 | -17.2% | -31.6% | 6.9% | 62.26% |
| 2015 | -7.3% | -20.4% | 13.8% | 77.67% |
| Period | PHSZX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 2.6% | 0.0% | 6.1% | 26.36% |
| 1 Yr | 18.6% | 2.6% | 41.8% | 39.50% |
| 3 Yr | 14.6%* | -9.3% | 30.8% | 25.69% |
| 5 Yr | 6.3%* | -9.8% | 16.7% | 40.57% |
| 10 Yr | 17.1%* | -0.5% | 18.8% | 7.69% |
* Annualized
| Period | PHSZX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2019 | 15.2% | 5.7% | 55.4% | 73.95% |
| 2018 | -13.5% | -25.3% | 22.2% | 82.88% |
| 2017 | 25.8% | -10.8% | 45.8% | 16.51% |
| 2016 | -17.2% | -26.4% | 8.7% | 74.53% |
| 2015 | -7.3% | -16.6% | 15.2% | 82.52% |
| PHSZX | Category Low | Category High | PHSZX % Rank | |
|---|---|---|---|---|
| Net Assets | 1.9 B | 3.58 M | 48.1 B | 26.77% |
| Number of Holdings | 72 | 18 | 399 | 64.34% |
| Net Assets in Top 10 | 735 M | 71.5 K | 17.4 B | 26.36% |
| Weighting of Top 10 | 38.45% | 21.3% | 75.3% | 57.36% |
| Weighting | Return Low | Return High | PHSZX % Rank | |
|---|---|---|---|---|
| Stocks | 99.11% | 48.12% | 103.54% | 30.23% |
| Cash | 0.79% | 0.00% | 51.88% | 55.81% |
| Other | 0.10% | -27.41% | 5.17% | 37.98% |
| Preferred Stocks | 0.00% | 0.00% | 1.08% | 41.09% |
| Convertible Bonds | 0.00% | 0.00% | 1.54% | 34.88% |
| Bonds | 0.00% | 0.00% | 20.60% | 31.01% |
| Weighting | Return Low | Return High | PHSZX % Rank | |
|---|---|---|---|---|
| Healthcare | 98.85% | 58.44% | 100.00% | 72.09% |
| Basic Materials | 0.82% | 0.00% | 2.02% | 3.88% |
| Financial Services | 0.33% | 0.00% | 6.09% | 11.63% |
| Utilities | 0.00% | 0.00% | 0.00% | 27.13% |
| Technology | 0.00% | 0.00% | 16.36% | 48.06% |
| Real Estate | 0.00% | 0.00% | 5.84% | 34.11% |
| Industrials | 0.00% | 0.00% | 2.40% | 35.66% |
| Energy | 0.00% | 0.00% | 0.43% | 31.78% |
| Communication Services | 0.00% | 0.00% | 1.02% | 31.78% |
| Consumer Defense | 0.00% | 0.00% | 36.20% | 33.33% |
| Consumer Cyclical | 0.00% | 0.00% | 10.50% | 34.11% |
| Weighting | Return Low | Return High | PHSZX % Rank | |
|---|---|---|---|---|
| US | 88.96% | 48.12% | 99.93% | 20.93% |
| Non US | 10.15% | 0.00% | 39.36% | 73.64% |
| PHSZX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.85% | 0.10% | 9.84% | 80.31% |
| Management Fee | 0.72% | 0.09% | 1.30% | 51.94% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
| Administrative Fee | N/A | 0.03% | 0.40% | N/A |
| PHSZX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 2.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 5.00% | N/A |
| PHSZX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 2.00% | N/A |
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| PHSZX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 36.00% | 0.00% | 341.00% | 47.58% |
| PHSZX | Category Low | Category High | PHSZX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 5.20% | 36.43% |
| PHSZX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
| PHSZX | Category Low | Category High | PHSZX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.34% | -2.24% | 2.12% | 64.57% |
| PHSZX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Annually | Annually |
Start Date
Tenure
Tenure Rank
Jun 30, 1999
20.52
20.5%
David Chan, CFA, is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Mr. Chan joined Jennison Associates in May 1992. He was previously with the Boston Consulting Group, where he was a team leader and consultant on projects in a wide variety of industries, but with a special focus in the health care area. Mr. Chan has also worked in various positions in the film and television industry. He received a BA in biochemistry from Harvard University and an MBA from Columbia University.
Start Date
Tenure
Tenure Rank
Jan 28, 2015
4.93
4.9%
Debra Netschert is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Ms. Netschert joined Jennison Associates in January 2008. Prior to Jennison, Ms. Netschert worked at Magnetar Capital where she was a senior analyst responsible for health care coverage with an emphasis on biotechnology and pharmaceutical industries. Prior to her experience at Magnetar Capital, Ms. Netschert worked at Amaranth Advisors as a biotechnology analyst. From 2002 to 2004, she was vice president and senior analyst for biotechnology at Lazard Capital Markets. Ms. Netschert began her research career as an associate biotechnology analyst at UBS in 2000. She received her BS and MS from Boston University.
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.59 | 22.31 | 9.83 | 19.68 |
TAXATION
For mutual fund investors, taxes are inevitable. Even if you’re a long-term buy...
MUTUAL FUND EDUCATION
Many investors assume that changes in a mutual fund’s net asset value (NAV)...
MUTUAL FUND EDUCATION
For investors looking to add mutual funds to their portfolio, they need to...
